BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference


10/23/2007 6:49:26 AM

BURLINGTON, Mass., Oct. 23 /PRNewswire/ -- CorNova, Inc. announced today that S. Eric Ryan, M.D., Chairman & CEO of CorNova, presented preliminary results of its recent preclinical studies for CorNova's Valecor Platinum(TM) Coronary Stent System at the TCT 2007 conference in Washington, D.C. The independently-conducted preclinical studies illustrated what CorNova believes to be meaningful improvements in neointimal proliferation, arterial injury, arterial inflammation, and reendothelialization when compared to a market-leading bare stent in rabbit and porcine models.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070206/CLTU213LOGO )

Commenting on today's announcement, Dr. Ryan stated, "We are very pleased with the results from these preclinical studies of our Valecor Platinum(TM) Stent, which is designed to maximize biocompatibility while minimizing arterial injury, potentially providing both short and long-term benefits over current bare stent technology. We also believe our Valecor Platinum(TM) Stent may offer the potential of improving coronary stent performance without the need for drug-elution and the inherent risks presented by drug-eluting stents. The Company is proceeding with its efforts to receive CE Mark approval for the Valecor Platinum(TM) Stent and we currently expect to receive that approval in early 2008."

About CorNova

CorNova, Inc., founded in 2003, is a privately-held, development-stage company with an experienced international team of business, medical, and engineering professionals within the field of interventional cardiology. CorNova's business focus is to build value and opportunity through the utilization of the technologies, expertise, and resources of its international team and partner companies to develop and sell innovative endovascular devices. The Company's strategic partners include Implant Sciences Corporation and CardioTech International, Inc. .



CONTACT: Timothy Looney of CorNova, Inc., +1-781-270-0055,
info@cornova.com

Web site: http://www.cornova.com/



Read at BioSpace.com

CorNova
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES